Authored by Harry Lee and Steve Lance via The Epoch Times (emphasis ours),
COVID-19 can be stopped without massive vaccination, renowned cardiologist and epidemiologist Dr. Peter McCullough told NTD’s “Capitol Report” program during the “Defeat the Mandates” march in Washington D.C., on Jan. 23.
According to McCullough, early treatment and natural immunity are safe and effective against COVID-19, but federal health agencies have ignored these in a push for vaccines, the broad use of which is not needed.
“The government has certainly been in an oblivion in terms of early treatment,” he said.
Thousands of people turned out to march in protest against COVID-19 vaccine mandates—one of the largest U.S. events against the mandates since the start of the pandemic.
“Our CDC, FDA, and NIH have had no effective messaging on early treatment, even the emergency use authorized monoclonal antibodies, which are safe and effective,” McCullough said. “And even on the new Merck and Pfizer drugs, which they’re basically absent in terms of the media, despite being recently distributed across the United States.”
Early effective treatment of any disease can help avert progression to more serious illness, with an additional benefit of reducing the burden on health care systems, and in a seperate interview, McCullough claimed that 95% of the COVID deaths could have been prevented by early treatment...
Dr. Peter McCullough @P_McCulloughMD says there was a predecided plan by our health agencies to suppress early treatment in order to promote mass vaccination at all cost and 95% of our population that died could of been prevented. pic.twitter.com/9sFvyeOynk— McCullough For Director NIH (@I7Bomb) January 27, 2022
The Centers for Disease Control and Prevention (CDC) stated on its website that according to the COVID-19 Treatment Guidelines published by the National Institutes of Health (NIH), “current clinical management of COVID-19 consists of infection prevention and control measures and supportive care, including supplemental oxygen and mechanical ventilatory support when indicated.”
The Food and Drug Administration (FDA) has approved one drug, remdesivir (Veklury), to treat COVID-19 in hospitalized patients, the CDC continued.
On Monday, the FDA announced that it is restricting the use of two monoclonal antibody treatments for COVID-19, saying data show such treatments are “highly unlikely” to be active against the Omicron variant.
McCullough said that highly qualified doctors have done the research and have shown that “early treatment can end this pandemic by reducing the intensity and severity of disease and reducing the chances of hospitalization and death in our highest risk seniors.”
“This basically means that the vaccines broadly used aren’t needed. And in fact, we have seen far too many vaccine injuries and now vaccine failures. With the Omicron variant, there’s effectively no coverage of these vaccines against the newest form of the virus,” McCullough said, adding 22 studies showed vaccines ran out of efficacy after six months.
McCullough gave the example of how ivermectin, a Nobel prize-winning, FDA-approved drug that many studies and doctors claim is effective in treating COVID-19 patients, was dismissed by federal health agencies.
The FDA has been saying the drug was approved to treat internal and external parasites, and currently no data shows its effectiveness against COVID-19.
McCullough also claimed that the federal health agencies have ignored natural immunity, which is “robust, complete, and durable in terms of the lethal strains of the virus.”
“It was only until it got to the Omicron variant, which there was a breakthrough, and individuals who are previously immune could get a mild Omicron syndrome. But natural immunity is the end of the pandemic,” McCullough continued. “Remember, as we all become naturally immune, COVID-19 is no longer a threat to our lives.
“And the failure of our governmental agencies to recognize natural immunity has basically created unnecessary suffering, unnecessary testing, unnecessary masking and social distancing. Unnecessary compliance with all kinds of measures that are designed for the susceptible. Those who are naturally immune are no longer susceptible to fatal disease.”
McCullough expressed doubt about the claim that COVID-19 vaccines could reduce hospitalization and deaths.
“All we have at this point of time is bias-confounded, and I think invalid hospitalization data. The U.S. agencies still make the claim that the vaccines protect against hospitalization, whereas we see no evidence of that in the UK, Germany, South Africa, and the rest of the world,” McCullough said. “And I can tell you, the United States is not that different than the rest of these countries. Something is wrong. And I can tell you something is wrong with an incorrect, invalid claim that the vaccines reduce hospitalization. I don’t think it’s supportable.”
On Jan. 19, the CDC published a study showing that people who had not gotten a vaccine but did have a prior infection, also known as natural immunity, were less likely to land in a hospital than the vaccinated without natural immunity.
The Epoch Times has contacted CDC for additional comment.
Last month, President Joe Biden announced new measures to battle COVID-19, the top three of which are boosters for all adults, vaccinations to protect kids, and expanding free at-home testing. Biden did talk about the new treatment, saying that “if and when any new COVID-19 treatment pills have been found to meet FDA’s scientific standards, they are equitably accessible to all Americans.”
Zachary Stieber contributed to this report.
After mass shootings like Uvalde, national gun control fails – but states often loosen gun laws
After mass shootings, politicians in Washington have failed to pass new gun control legislation, despite public pressure. But laws are being passed at…
Calls for new gun legislation that previously failed to pass Congress are being raised again after the May 24, 2022, mass shooting at an elementary school in the small town of Uvalde, Texas.
The U.S. has been here before – after shootings in Tucson, Aurora, Newtown, Charleston, Roseburg, San Bernardino, Orlando, Las Vegas, Parkland, El Paso, Boulder, and 12 days earlier at a grocery store in Buffalo, N.Y.
Senator Chris Murphy of Connecticut was among the Democratic politicians who pleaded for action on gun control as horrifying details of the Uvalde school shooting unfolded.
“What are we doing?” Murphy asked other lawmakers, speaking from the Senate floor on the day of the shooting. “Why are you here if not to solve a problem as existential as this?”
Congress has declined to pass significant new gun legislation after dozens of shootings, including those that occurred during periods like this one, with Democrats controlling the House of Representatives, Senate and presidency.
This response may seem puzzling given that national opinion polls reveal extensive support for several gun control policies, including expanding background checks and banning assault weapons.
In October 2021, 52% of people polled by Gallup said that they thought firearm sales laws should be made more strict.
I am a professor of strategy at UCLA and have researched gun policy. With my co-authors at Harvard University, I’ve studied how gun laws change following mass shootings.
Our research on this topic finds there is legislative activity following these tragedies, but it’s at the state level.
Stricter gun laws at the national level are more popular among Democrats than Republicans, and major new legislation would likely need votes from at least 10 Republican senators. Many of these senators represent constituencies opposed to gun control.
Despite national polls showing majority support for an assault weapons ban, not one of the 30 states with a Republican-controlled legislature has such a policy.
U.S. Texas Senator Ted Cruz said on May 24 that more gun control laws could not have prevented the Uvalde attack, explaining “that doesn’t work, it’s not effective, it doesn’t prevent crime.”
The absence of strict control policies in Republican-controlled states shows that senators crossing party lines to support gun control would be out of step with the views of voters whose support they need to win elections.
But a lack of action from Congress doesn’t mean gun laws are stagnant after mass shootings.
To examine how policy changes, we assembled data on shootings and gun legislation in the 50 states between 1990 and 2014. Overall, we identified more than 20,000 firearm bills and nearly 3,200 enacted laws. Some of these loosened gun restrictions, others tightened them, and still others did neither or both – that is, tightened in some dimensions but loosened in others.
We then compared gun laws before and after mass shootings in states where mass shootings occurred, relative to all other states.
Contrary to the view that nothing changes, state legislatures consider 15% more firearm bills the year after a mass shooting. Deadlier shootings – which receive more media attention – have larger effects.
In fact, mass shootings have a greater influence on lawmakers than other homicides, even though they account for less than 1% of gun deaths in the United States.
As impressive as this 15% increase in gun bills may sound, gun legislation can reduce gun violence only if it becomes law. And when it comes to enacting these bills into law, our research found that mass shootings do not regularly cause lawmakers to tighten gun restrictions.
In fact, we found the opposite. Republican state legislatures pass significantly more gun laws that loosen restrictions on firearms after mass shootings.
In 2021, Texas Governor Greg Abbott signed a new law that eliminated a requirement for Texans to obtain a license or receive training to carry handguns. This came two years after a 2019 mass shooting at a Walmart in El Paso.
That’s not to say Democrats never tighten gun laws – there are prominent examples of Democratic-controlled states passing new legislation following mass shootings.
California, for example, enacted several new gun laws following a 2015 mass shooting in San Bernardino. Our research shows, however, that Democrats don’t tighten gun laws more than usual following mass shootings.
After the Buffalo shooting in early May 2022, New York Governor Kathy Hochul said that she would work to increase the age for legal gun purchasing from 18 to 21 “at a minimum.”
Ideology governs response
The contrasting response from Democrats and Republicans is indicative of different philosophies regarding the causes of gun violence and the best ways to reduce deaths.
While Democrats tend to view social factors as contributing to violence, Republicans are more likely to blame the individual shooters.
Cruz, for example, has said that stopping individuals with criminal records from committing violence could help prevent mass shootings.
Politicians favoring looser restrictions on guns following mass shootings frequently argue that more people carrying guns would allow law-abiding citizens to stop perpetrators.
In fact, gun sales often surge after mass shootings, in part because people fear being victimized.
Democrats, in contrast, typically focus more on trying to solve policy and societal problems that contribute to gun violence.
For both sides, mass shootings are an opportunity to propose bills consistent with their ideology.
Since we wrote our study of gun legislation following mass shootings, which covered the period through 2014, several additional tragedies have energized the gun control movement that emerged following the December 2012 shooting at Sandy Hook Elementary School in Connecticut. These include the May 2022 shooting at the Tops grocery store in Buffalo, as well as the Uvalde school massacre.
Student activism following the 2018 shooting at Marjory Stoneman Douglas High School in Parkland, Florida, did not result in congressional action but led several states to pass new gun control laws.
With more funding and better organization, this new movement is better positioned than prior gun control movements to advocate for stricter gun policies following mass shootings. Public outcry and devastation over the Uvalde shootings will likely provide fuel to this advocacy work.
But with states historically more active than Congress on the issue of guns, both advocates and opponents of new restrictions should look beyond Washington for action on gun policy.
This is an updated version of an article originally published on March 21, 2021.
Christopher Poliquin does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.congress senate house of representatives governor pandemic covid-19 deaths
5 Top Consumer Stocks To Watch Right Now
Are these consumer stocks a buy amid the earnings season?
The post 5 Top Consumer Stocks To Watch Right Now appeared first on Stock Market News, Quotes,…
5 Trending Consumer Stocks To Watch In The Stock Market Now
As we tread through the earnings season, consumer stocks could be worth watching in the stock market this week. This would be the case since a number of big consumer names such as Costco (NASDAQ: COST) and Macy’s (NYSE: M) will be posting their financials for the quarter. As such, investors will be keeping an eye on these reports for clues on the strength of consumer spending amid this period of high inflation.
However, despite the soaring prices across the economy, it seems that consumers are surprisingly showing resilience. According to the Commerce Department, retail sales in April outpaced inflation for a fourth straight month. This could suggest that consumers as a whole were not only sustaining their spending, but spending more even after adjusting for inflation. Ultimately, it could be a reassuring sign that consumers are still supporting the economy and helping to diminish the narrative of an incoming recession. With that being said, here are five consumer stocks to check out in the stock market today.
Consumer Stocks To Buy [Or Sell] Right Now
- Nordstrom Inc. (NYSE: JWN)
- The Wendy’s Company (NASDAQ: WEN)
- Foot Locker Inc. (NYSE: FL)
- Tyson Foods Inc. (NYSE: TSN)
- DoorDash Inc. (NYSE: DASH)
Starting off our list of consumer stocks today is Nordstrom. For the most part, it is a fashion retailer of full-line luxury apparel, footwear, accessories, and cosmetics among others. The company operates through multiple retail channels, boutiques, and online as well. As it stands, Nordstrom operates around 100 stores in 32 states in the U.S. and three Canadian provinces.
Yesterday, the company reported its financials for the first quarter of 2022. Starting with revenue, Nordstrom pulled in net sales worth $3.47 million for the quarter. This marks an increase of 18.7% from the same quarter last year. Its Nordstrom banner saw net sales rise by 23.5% year-over-year, exceeding pre-pandemic levels. Next to that, its Nordstrom Rack banner saw a 10.3% increase in net sales from last year. Besides, net earnings were $20 million, with earnings per share of $0.13 for the quarter. Considering Nordstrom’s solid quarter, should you invest in JWN stock?
The Wendy’s Company
Next up, we have The Wendy’s Company. For the most part, it is the holding company for the major fast-food chain, Wendy’s. Being one of the world’s largest hamburger fast-food chains, the company boasts over 6,500 restaurants in the U.S. and 29 other countries. The chain is known for its square hamburgers, sea salt fries, and the Frosty, a form of soft-serve ice cream mixed with starches. WEN stock is rising by over 8% on today’s opening bell.
According to an SEC filing, Wendy’s largest shareholder, Trian Partners, is looking into making a potential deal with the company. Trian said that it is considering a deal to “enhance shareholder value.” Also, the firm adds that this could lead to an acquisition or business combination. In response, Wendy’s stated that it is constantly reviewing strategic priorities and opportunities. It added that the company’s board will carefully review any proposal from Trian. Given this piece of news, will you be watching WEN stock?
Another stock investors could be watching is the shoes and apparel company, Foot Locker. In brief, the company uses its omnichannel capabilities to bridge the digital world and physical stores. As such, it provides buy online and pickup-in-store services, order-in-store, as well as the growing trend of e-commerce. Some of its most notable brands include Eastbay, Footaction, Foot Locker, Champs Sports, and Sidestep. Last week, the company reported its results for the first quarter of the year.
For starters, total sales came in at $2.175 billion, a slight uptick compared to sales of $2.153 billion in the year prior. Next to that, Foot Locker reported a net income of $133 million. Accordingly, adjusted earnings per share came in at $1.60, beating Wall Street’s expectations of $1.54. CEO Richard Johnson added, “Our progress in broadening and enriching our assortment continues to meet our customers’ demand for choice. These efforts helped drive our strong results in the first quarter, which will allow us to more fully participate in the robust growth of our category going forward.” As such, is FL stock one to add to your watchlist?
Tyson Foods is a company that built its name on providing families with wholesome and great-tasting protein products. Its segments include Beef, Pork, Chicken, and Prepared Foods. With some of the fastest-growing portfolio of protein-centric brands, it should not be surprising that TSN stock often comes to mind when investors are looking for the best consumer stocks to buy.
Earlier this month, Tyson Foods provided its fiscal second-quarter financial update. The company’s total sales for the quarter were $13.1 billion, representing an increase of 15.9% compared to the prior year’s quarter. Meanwhile, its GAAP earnings per share climbed to $2.28, up 75% year-over-year. According to Tyson, these financial figures are a reflection of the increasing consumer demand for its brands and products. To top it off, the company was also able to reduce its total debt by approximately $1 billion. Thus, does TSN stock have a spot on your watchlist?
DoorDash is a consumer company that operates an online food ordering and delivery platform. In fact, it is one of the largest delivery companies in the U.S. and enjoys a huge market share. The company connects hundreds of thousands of merchants to over 25 million consumers in the U.S., Canada, Australia, and Japan through its local logistics platform. Accordingly, its platform allows local businesses to thrive in today’s “convenience economy,” as the company puts it.
On May 5, the company reported its first-quarter financials for 2022. Diving in, it posted a revenue of $1.5 billion, growing by 35% year-over-year. This was driven by total orders that grew by 23% year-over-year to $404 million. Along with that, it reported a GAAP gross profit of $662 million, an increase of 34% year-over-year. The company said that it added more consumers than any quarter since Q1 2021, due in part to the growth of its DashPass members. The growth in Monthly Active Users and average order frequency has helped it gain share in the U.S. Food Delivery category this quarter as well. Given DoorDash’s performance for the quarter, should you watch DASH stock?
If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!recession pandemic dow jones sp 500 nasdaq stocks consumer spending japan canada
Finding Shelter in an Inverse ETF
As the old saying goes, “What goes up must come down.” Indeed, up until the recent selling wave caused by Russia’s war against Ukraine and the continued…
As the old saying goes, “What goes up must come down.”
Indeed, up until the recent selling wave caused by Russia’s war against Ukraine and the continued effects of supply chain disruptions amid the COVID-19 pandemic, tech stocks, including semiconductors, were the darlings of the investment world. That is, it seemed as if the sky-high valuations of some tech stocks were sustainable in an atmosphere of seemingly perpetual growth.
That, of course, was not the case, and the too-good-to-be-true valuations were quickly brought down to earth by the forces of inflation and tight monetary policy. As a result, the tech-heavy Nasdaq entered a free-fall that has not yet found a bottom.
At the same time, that does not mean that we should abandon the sector as a lost cause. One such way to play the sector during its downhill slide is the exchange-traded fund (ETF) Direxion Daily Semiconductor Bear 3X Shares (NYSEARCA: SOXS).
As its title suggests, this is an inverse ETF, meaning that it is built to go up in value when its parent index goes down. Specifically, SOXS provides three times leveraged inverse exposure to a modified market-cap-weighted index of semiconductor companies that trade in American markets by using swap agreements, futures contracts and short positions.
While the index’s holdings are weighted by market capitalization, the fund’s managers cap the weights of the top five securities in the portfolio at 8% each. The weight of the remaining securities is capped at 4% each.
As of May 24, SOXS has been up 0.37% over the past month and up 24.73% for the past three months. It is currently up 60.47% year to date.
Chart courtesy of www.stockcharts.com
The fund has amassed $258.15 million in assets under management and has an expense ratio of 1.01%.
In short, while SOXS does provide an investor with a way to invest in an inverse ETF, this kind of ETF may not be appropriate for all portfolios. Thus, interested investors always should conduct their due diligence and decide whether the fund is suitable for their investing goals.
As always, I am happy to answer any of your questions about ETFs, so do not hesitate to send me an email. You just may see your question answered in a future ETF Talk.nasdaq stocks pandemic covid-19 monetary policy etf russia ukraine
Six Commodities Investments to Buy as Putin Wages War on Ukraine
Moderna CEO Laments ‘Throwing 30 Million Doses In The Garbage Because Nobody Wants Them’
Pfizer Moves To Dismiss Lawsuit From COVID-19 Vaccine Trial, Citing ‘Prototype’ Agreement
Shanghai: world’s biggest port is returning to normal, but supply chains will get worse before they get better
PLS market is on track to notch record volume this year
Formula Shortage Highlights Supply Chain Concerns Facing Pharma Industry
Another Month Closer To Global Recession
UK’s Johnson Urges Talks As Unions Threaten “Biggest Rail Strike In Modern History”
Five Major Challenges Facing The Energy Industry
How Inflation Changed The Price Of A Burger
Government17 hours ago
Six Commodities Investments to Buy as Putin Wages War on Ukraine
Science20 hours ago
Moderna CEO Laments ‘Throwing 30 Million Doses In The Garbage Because Nobody Wants Them’
Economics22 hours ago
Banks Face Trouble As Credit Cycle Turns
Economics18 hours ago
Middle East container ports are the most efficient in the world
Economics23 hours ago
Another Month Closer To Global Recession
Science13 hours ago
Pfizer makes non-profit pledge for low-income nations
Stocks24 hours ago
Skyworks is deep in the oversold zone but is it the right time to buy?
Government23 hours ago
60,000 Migrants Waiting In Mexico Across Border From El Paso, Texas